search
Back to results

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)

Primary Purpose

HSV Infection

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Pritelivir
Foscarnet
Sponsored by
AiCuris Anti-infective Cures AG
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HSV Infection

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Part C inclusion criteria

  1. Immunocompromised men and women of any ethnic group aged ≥16 years.

    In Canada, Germany, Belgium:

    Immunocompromised (due to conditions including HIV infection, hematopoietic cell or solid organ transplantation, and chronic glucocorticoid use) men and women of any ethnic group aged >18 years.

  2. ACV-R mucocutaneous HSV infection based on clinical failure, requiring switch to foscarnet treatment or positive genotypic/phenotypic ACV resistance testing for current lesion. Clinical failure is defined as no improvement after oral or iv doses for at least 7 days withat doses equivalent to or greater than the local agency approved high oral doses withof acyclovir, (800 mg TID) or valacyclovir or famciclovir.(1 g TID).
  3. Lesions accessible for visual inspection to allow assessment of lesion healing including visualization by endoscopy or pharyngoscopy.
  4. Willingness to abstain from the application of lotions and/or creams to the area with HSV lesions. Wet/dry saline dressings or bandages at lesion site are allowed.
  5. Willingness to use highly effective birth control.
  6. Subject, and/or their legally authorized representative, (proxy consent is not permitted in Germany), must be willing and able to understand the Informed Consent Form.
  7. Negative serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential at Screening and a negative urine pregnancy test at Day 1.
  8. Written informed consent. For subjects, who are unable to provide informed consent for whatever reason, written consent must be obtained from the legal representative, (proxy consent is not permitted in Germany).

Part D and F inclusion criteria

All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:

2. ACV-R and foscarnet-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic resistance testing for current lesion or documented intolerance to iv foscarnet requiring cessation of foscarnet treatment or precluding foscarnet treatment.

Subjects will be able to enter Part F only after closure of enrollment in Part D.

Part E inclusion (Part E is not being conducted in Germany)

All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:

2. Recurrent mucocutaneous HSV infection considered ACV-S.

Part C exclusion criteria

  1. Known resistance/intolerance to pritelivir and/or foscarnet or any of the excipients.
  2. Previous treatment in PRIOH-1.
  3. Need to use paclitaxel.
  4. Baseline safety laboratory abnormalities.
  5. History or current evidence of gastrointestinal malabsorption which, in the opinion of the Investigator, may affect the extent of absorption of pritelivir.
  6. Severe renal insufficiency (eGFR ≤29 mL/min/1.73 m2).
  7. History or current evidence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other relevant diseases.
  8. Abnormalities in hematological, clinical chemical or any other laboratory variables.
  9. Not able to communicate meaningfully with the Investigator and site staff.
  10. Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial.
  11. Any other important local condition.
  12. Pregnant and/or breastfeeding women.
  13. Having received an investigational drug in an investigational drug trial unter certain conditions.

Part D exclusion criteria

All exclusion criteria as for Part C, except for exclusion criterion 1, which is replaced by: 1. Known intolerance to pritelivir or any of the excipients and except criterion 13, which is replaced by: 13. Having received an investigational drug in an investigational drug within 7 half-lives after the last administration of this drug before initiating trial medication, except for subjects entering Part D, who have previously received foscarnet treatment in Part C of this trial.

Participation in a clinical trial without receiving other investigational drugs (eg, follow-up phase of a trial, observational study) is permitted.

Part E exclusion criteria (Part E is not being conducted in Germany)

All exclusion criteria as for Part C, except for exclusion criteria 1, which is replaced by

1. known intolerance to pritelivir or any of the excipients and addition of 14. Having used (val)acyclovir within 3 days prior to starting pritelivir.

Part F exclusion criteria All exclusion criteria for Part D plus 14. Part D open for enrollment

Sites / Locations

  • University of Alabama at BirminghamRecruiting
  • University Arizona - Department of Medicine Arizona Health Sciences CenterRecruiting
  • City of HopeRecruiting
  • Cedars-Sinai Medical CenterRecruiting
  • University of California, Division of Infectious DiseasesRecruiting
  • IMMUNOe International Research Centers
  • Yale University School of Medicine - Infectious DiseasesRecruiting
  • Midland Florida Clinical Research Center, LLCRecruiting
  • Midway Immunology and Research Center (MIRC)Recruiting
  • University of Florida (UF) - Division of Infectious DiseaseRecruiting
  • Palmetto Professional ResearchRecruiting
  • Links Clinical TrialsRecruiting
  • Emory Hospital Midtown Infectious Disease ClinicRecruiting
  • Department of Medicine J. H. Stroger Hospital of Cook CountyRecruiting
  • LSU Health Baton Rouge Pulmonary ClinicRecruiting
  • Johns Hopkins University School of MedicineRecruiting
  • Massachusetts General HospitalRecruiting
  • Brigham and Women's HospitalRecruiting
  • Wayne State University
  • University of Nebraska Medical CenterRecruiting
  • David H. Koch Center at Memorial Sloan Kettering Cancer CenterRecruiting
  • Atrium Health Wake Forest BaptistRecruiting
  • Cincinnati Children's Hospital Medical CenterRecruiting
  • University of Pittsburgh Medical CenterRecruiting
  • MD Anderson Cancer CenterRecruiting
  • Fred Hutchinson Cancer Research CenterRecruiting
  • Hospital RawsonRecruiting
  • Sanatorio Mayo Privado S.A.Recruiting
  • Instituto FIDESRecruiting
  • Melbourne Health - Royal Melbourne HospitalRecruiting
  • Westmead Hospital, Centre for Infectious Disease and MicrobiologyRecruiting
  • Centre Hospitalier Universitaire Saint PierreRecruiting
  • AZ DeltaRecruiting
  • Alberta Health Services Cross Cancer Institute at the University of AlbertaRecruiting
  • Beijing Ditan Hospital Capital Medical University
  • CHU Limoges - Centre national de reference des Herpes virusRecruiting
  • CHU de NantesRecruiting
  • Hôpital Saint Louis - AP-HPRecruiting
  • AP-HP Hopital Necker-Enfants MaladesRecruiting
  • AP-HP Hopital Bichat - Claude BernardRecruiting
  • LLC DiakorRecruiting
  • JSC CuratioRecruiting
  • Multiprofile Clinic Consilium Medulla LTDRecruiting
  • Universitätsklinikum KölnRecruiting
  • Muenchen Klinik NeuperlachRecruiting
  • General Hospital of Athens - LaikoRecruiting
  • Regional University General Hospital of HeraklionRecruiting
  • Chaim Sheba Medical CenterRecruiting
  • Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"Recruiting
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MilanoRecruiting
  • Fondazione IRCCS Policlinico San MatteoRecruiting
  • Centro de Investigacion Clinica GRAMEL S.C.Recruiting
  • Instituto de Investigaciones Aplicadas a la Neurociencia A.CRecruiting
  • Centro de Investigacion Farmaceutica Especializado de Occidente S.C.Recruiting
  • Unidad de Investigacion CIMA SCRecruiting
  • Clinical Research Institute Saltillo S.A de C.V
  • Arke SMO S.A. de C.V.Recruiting
  • Universitaetsspital Basel Ambulantes Studienzentrum
  • Hopitaux universitaires de GeneveRecruiting
  • Universitaetsspital ZuerichRecruiting
  • Chelsea and Westminster HospitalRecruiting
  • Research Department of Haematology, UCL Cancer InstituteRecruiting
  • Freeman HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Active Comparator

Experimental

Experimental

Experimental

Arm Label

Part C, Pritelivir

Part C, Foscarnet

Part D, Pritelivir

Part E, Pritelivir

Part F, Pritelivir

Arm Description

Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days

iv solution, 40 mg/kg tid or 60mg/kg bid for up to 28 days and potential prolongation for up to additional 14 days.

Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days

Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days

Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days

Outcomes

Primary Outcome Measures

Efficacy measured by cure rate
Number of subjects cured (all lesions healed as assessed by the Investigator) during the treatment period of up to 28 days relative to the total number of subjects treated with trial medication in the respective treatment group.

Secondary Outcome Measures

Efficacy measured by cure rate
Number of subjects cured (all lesions healed as assessed by the Investigator) during the treatment period of up to 42 days relative to the total number of subjects treated with trial medication in the respective treatment group.
Efficacy measured by time to lesion healing
Time to lesion healing, defined as complete epithelization of the mucocutaneous HSV lesion(s) within the treatment period and no appearance of new lesions, as assessed by the Investigator.
Efficacy measured by recurrence rate
Recurrence rate at 2 months following PoTV assessed by telephone, defined as number of subjects with a recurrence as assessed by the Investigator following 2/3 months after PoTV relative to the total number of subjects assessed for recurrence at the respective telephone call per treatment.
Efficacy measured by recurrence rate
Recurrence rate at 3 months following PoTV assessed by telephone, defined as number of subjects with a recurrence as assessed by the Investigator following 2/3 months after PoTV relative to the total number of subjects assessed for recurrence at the respective telephone call per treatment.
Efficacy measured by pain rate
Number of days with pain at lesion site relative to the total number of days with analyzable pain data through daily subject self-reporting
Efficacy measured by time to pain cessation at site of lesion
Starting at first dose of trial medication until pain is no longer reported by the subject (date and time)
Efficacy measured by average pain score
Using a single-dimensional scale assessing pain intensity through daily subject self-reporting
Efficacy measured by clinical shedding rate
Number of HSV positive swabs per subject relative to the total number of swabs collected per subject from lesion swabs taken from HSV lesion(s)
Efficacy measured by time to cessation of shedding
Number of days until swabs taken are negative
Efficacy measured by mean log number of HSV DNA copies
Mean log number of HSV DNA copies on HSV DNA positive swabs from lesion(s) as detected by quantitative real-time PCR (polymerase chain reaction).
Efficacy measured by resistance to trial medication
Resistance to trial medication for lesions not healed within the treatment period or newly appeared lesions under treatment before or at the PoTV.
Safety measured by number of subjects developing chronic kidney disease
Chronic kidney disease
Safety measured by percentage of subjects developing chronic kidney disease
Chronic kidney disease
Safety measured by number of subjects developing acute Kidney Injury
Acute Kidney Injury (AKI) stage >1 of KDIGO (Kidney Disease: Improving Global Outcome) criteria (increase in serum creatinine by 2.0 to 2.9 times compared to baseline or urine output <0.5 mL/kg/h for >12 hours)
Safety measured by number of subjects developing renal impairment
Renal impairment
Safety measured by percentage of subjects developing renal impairment
Renal impairment
Safety measured by number of subjects developing electrolyte abnormality
All abnormal values
Safety measured by number of subjects developing seizures
All seizures
Safety measured by number of subjects developing anemia
Haemoglobin measurement
Safety measured by adverse events
Incidence of Adverse Events
Safety measured by haematology
Incidence of abnormal hematologic laboratory test results
Safety measured by lymphadenopathy
Incidence of lymphadenopathy measured by physical examination
Safety measured by CRP (C reactive protein )
Incidence of CRP increase
Safety measured by cutaneous adverse events
Incidence of cutaneous adverse events by physical examination
Safety measured by (a)PTT (partial thromboplastin time)
Incidence of (a)PTT increase
Safety measured by discontinuation rate
Number of subjects discontinuing pritelivir or foscarnet due to AE(s) or intolerance relative to the total number of subjects treated with pritelivir or foscarnet, respectively

Full Information

First Posted
March 3, 2017
Last Updated
October 4, 2023
Sponsor
AiCuris Anti-infective Cures AG
Collaborators
Medpace, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03073967
Brief Title
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
Acronym
PRIOH-1
Official Title
A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir Versus Foscarnet for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 8, 2017 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AiCuris Anti-infective Cures AG
Collaborators
Medpace, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours.
Detailed Description
The trial comprises 5 Parts, Part A, B, C, D, E and F. Part A and Part B (Phase 2) have been finalised. Part A is a randomized, open-label, multi-center, comparative design to assess the efficacy and safety in subjects with ACV-resistant mucocutaneous HSV infection, treated with oral pritelivir or intravenous foscarnet. Part B is an open-label, multi-center design to assess the efficacy and safety of pritelivir in subjects with ACV-resistant-mucocutaneous HSV and who either: present with foscarnet-resistance/intolerance, or developed foscarnet resistance/intolerance during treatment in Part A (no improvement after at least 5 days of foscarnet therapy or intolerance to foscarnet requiring cessation of foscarnet treatment). Parts C, D, E and F (Phase 3). Part C is a randomized, open-label, multi-center, comparative design to assess the efficacy and safety of oral pritelivir in subjects with acyclovir resistent (ACV-R) mucocutaneous HSV episodes. Subjects with ACV-R mucocutaneous HSV infection will be randomized 1:1 to receive either oral pritelivir or iv foscarnet. The trial is designed to show superiority of pritelivir against foscarnet in obtaining clinical cure, ie, number of subjects with all lesions healed within 28 days. Part D is an open-label, multi-center (performed in the same trial sites as Part C) design to assess the efficacy and safety of pritelivir in subjects with ACV-R mucocutaneous HSV episodes and who in addition either: present with iv foscarnet resistance/intolerance already at Screening for inclusion, or developed foscarnet resistance/intolerance during treatment in Part C (no improvement after at least 7 days of foscarnet treatment or intolerance to foscarnet requiring cessation of foscarnet treatment). Part D has been closed in June 2022. Part E is an open-label, multi-center (performed in the same trial sites as Part C) design to assess the safety and efficacy of pritelivir in subjects with acyclovir susceptible (ACV-S) mucocutaneous HSV episodes, (Part E is not beeing conducted in Germany). Part F is an open-label, multi-center (performed in the same trial sites as Part C) design to assess the efficacy and safety of pritelivir in subjects with ACV-R mucocutaneous HSV episodes and who in addition either: present with iv foscarnet resistance/intolerance already at Screening for inclusion, or developed foscarnet resistance/intolerance during treatment in Part C (no improvement after at least 7 days of foscarnet treatment or intolerance to foscarnet requiring cessation of foscarnet treatment). cannot be enrolled into Part D anymore because enrollment into Part D has been completed. Pritelivir trial medication will be given orally as single daily doses of 100 mg (following a loading dose of 400 mg as first dose) until all mucocutaneous HSV lesions are healed or up to 28 days, whichever is earlier. A prolongation up to a maximum of 42 days may be possible. Foscarnet will be given as intermittent infusions at a dose of 40 mg/kg every 8 hours or 60 mg/kg every 12 hours (to be adjusted in case of renal impairment) for a minimum of 1 hour duration until all mucocutaneous HSV lesions are healed or up to 28 days, whichever is earlier. A prolongation up to a maximum of 42 days may be possible.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HSV Infection

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
153 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part C, Pritelivir
Arm Type
Experimental
Arm Description
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
Arm Title
Part C, Foscarnet
Arm Type
Active Comparator
Arm Description
iv solution, 40 mg/kg tid or 60mg/kg bid for up to 28 days and potential prolongation for up to additional 14 days.
Arm Title
Part D, Pritelivir
Arm Type
Experimental
Arm Description
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
Arm Title
Part E, Pritelivir
Arm Type
Experimental
Arm Description
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
Arm Title
Part F, Pritelivir
Arm Type
Experimental
Arm Description
Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days
Intervention Type
Drug
Intervention Name(s)
Pritelivir
Intervention Description
100 mg tablets
Intervention Type
Drug
Intervention Name(s)
Foscarnet
Intervention Description
Solution for iv infusion
Primary Outcome Measure Information:
Title
Efficacy measured by cure rate
Description
Number of subjects cured (all lesions healed as assessed by the Investigator) during the treatment period of up to 28 days relative to the total number of subjects treated with trial medication in the respective treatment group.
Time Frame
Up to a maximum of 28 days
Secondary Outcome Measure Information:
Title
Efficacy measured by cure rate
Description
Number of subjects cured (all lesions healed as assessed by the Investigator) during the treatment period of up to 42 days relative to the total number of subjects treated with trial medication in the respective treatment group.
Time Frame
Up to a maximum of 42 days
Title
Efficacy measured by time to lesion healing
Description
Time to lesion healing, defined as complete epithelization of the mucocutaneous HSV lesion(s) within the treatment period and no appearance of new lesions, as assessed by the Investigator.
Time Frame
Up to a maximum of 42 days
Title
Efficacy measured by recurrence rate
Description
Recurrence rate at 2 months following PoTV assessed by telephone, defined as number of subjects with a recurrence as assessed by the Investigator following 2/3 months after PoTV relative to the total number of subjects assessed for recurrence at the respective telephone call per treatment.
Time Frame
At 2 months following post treatment visit, from randomization up to a maximum of 108 days
Title
Efficacy measured by recurrence rate
Description
Recurrence rate at 3 months following PoTV assessed by telephone, defined as number of subjects with a recurrence as assessed by the Investigator following 2/3 months after PoTV relative to the total number of subjects assessed for recurrence at the respective telephone call per treatment.
Time Frame
At 3 months following post treatment visit, from randomization up to a maximum of 139 days
Title
Efficacy measured by pain rate
Description
Number of days with pain at lesion site relative to the total number of days with analyzable pain data through daily subject self-reporting
Time Frame
Up to a maximum of 42 days
Title
Efficacy measured by time to pain cessation at site of lesion
Description
Starting at first dose of trial medication until pain is no longer reported by the subject (date and time)
Time Frame
Up to a maximum of 42 days
Title
Efficacy measured by average pain score
Description
Using a single-dimensional scale assessing pain intensity through daily subject self-reporting
Time Frame
Up to a maximum of 42 days
Title
Efficacy measured by clinical shedding rate
Description
Number of HSV positive swabs per subject relative to the total number of swabs collected per subject from lesion swabs taken from HSV lesion(s)
Time Frame
From date of randomization until the date of first documented healing, assessed up to a maximum of 42 days
Title
Efficacy measured by time to cessation of shedding
Description
Number of days until swabs taken are negative
Time Frame
Up to a maximum of 42 days
Title
Efficacy measured by mean log number of HSV DNA copies
Description
Mean log number of HSV DNA copies on HSV DNA positive swabs from lesion(s) as detected by quantitative real-time PCR (polymerase chain reaction).
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Efficacy measured by resistance to trial medication
Description
Resistance to trial medication for lesions not healed within the treatment period or newly appeared lesions under treatment before or at the PoTV.
Time Frame
From date of randomization until the date of post treatment visit, assessed up to a maximum of 73 days
Title
Safety measured by number of subjects developing chronic kidney disease
Description
Chronic kidney disease
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by percentage of subjects developing chronic kidney disease
Description
Chronic kidney disease
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by number of subjects developing acute Kidney Injury
Description
Acute Kidney Injury (AKI) stage >1 of KDIGO (Kidney Disease: Improving Global Outcome) criteria (increase in serum creatinine by 2.0 to 2.9 times compared to baseline or urine output <0.5 mL/kg/h for >12 hours)
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by number of subjects developing renal impairment
Description
Renal impairment
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by percentage of subjects developing renal impairment
Description
Renal impairment
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by number of subjects developing electrolyte abnormality
Description
All abnormal values
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by number of subjects developing seizures
Description
All seizures
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by number of subjects developing anemia
Description
Haemoglobin measurement
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by adverse events
Description
Incidence of Adverse Events
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by haematology
Description
Incidence of abnormal hematologic laboratory test results
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by lymphadenopathy
Description
Incidence of lymphadenopathy measured by physical examination
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by CRP (C reactive protein )
Description
Incidence of CRP increase
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by cutaneous adverse events
Description
Incidence of cutaneous adverse events by physical examination
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by (a)PTT (partial thromboplastin time)
Description
Incidence of (a)PTT increase
Time Frame
From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days
Title
Safety measured by discontinuation rate
Description
Number of subjects discontinuing pritelivir or foscarnet due to AE(s) or intolerance relative to the total number of subjects treated with pritelivir or foscarnet, respectively
Time Frame
Up to a maximum of 42 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Part C inclusion criteria Immunocompromised men and women of any ethnic group aged ≥16 years. In Canada, Germany, Belgium: Immunocompromised (due to conditions including HIV infection, hematopoietic cell or solid organ transplantation, and chronic glucocorticoid use) men and women of any ethnic group aged >18 years. ACV-R mucocutaneous HSV infection based on clinical failure, requiring switch to foscarnet treatment or positive genotypic/phenotypic ACV resistance testing for current lesion. Clinical failure is defined as no improvement after oral or iv doses for at least 7 days withat doses equivalent to or greater than the local agency approved high oral doses withof acyclovir, (800 mg TID) or valacyclovir or famciclovir.(1 g TID). Lesions accessible for visual inspection to allow assessment of lesion healing including visualization by endoscopy or pharyngoscopy. Willingness to abstain from the application of lotions and/or creams to the area with HSV lesions. Wet/dry saline dressings or bandages at lesion site are allowed. Willingness to use highly effective birth control. Subject, and/or their legally authorized representative, (proxy consent is not permitted in Germany), must be willing and able to understand the Informed Consent Form. Negative serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential at Screening and a negative urine pregnancy test at Day 1. Written informed consent. For subjects, who are unable to provide informed consent for whatever reason, written consent must be obtained from the legal representative, (proxy consent is not permitted in Germany). Part D and F inclusion criteria All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by: 2. ACV-R and foscarnet-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic resistance testing for current lesion or documented intolerance to iv foscarnet requiring cessation of foscarnet treatment or precluding foscarnet treatment. Subjects will be able to enter Part F only after closure of enrollment in Part D. Part E inclusion (Part E is not being conducted in Germany) All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by: 2. Recurrent mucocutaneous HSV infection considered ACV-S. Part C exclusion criteria Known resistance/intolerance to pritelivir and/or foscarnet or any of the excipients. Previous treatment in PRIOH-1. Need to use paclitaxel. Baseline safety laboratory abnormalities. History or current evidence of gastrointestinal malabsorption which, in the opinion of the Investigator, may affect the extent of absorption of pritelivir. Severe renal insufficiency (eGFR ≤29 mL/min/1.73 m2). History or current evidence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other relevant diseases. Abnormalities in hematological, clinical chemical or any other laboratory variables. Not able to communicate meaningfully with the Investigator and site staff. Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial. Any other important local condition. Pregnant and/or breastfeeding women. Having received an investigational drug in an investigational drug trial unter certain conditions. Part D exclusion criteria All exclusion criteria as for Part C, except for exclusion criterion 1, which is replaced by: 1. Known intolerance to pritelivir or any of the excipients and except criterion 13, which is replaced by: 13. Having received an investigational drug in an investigational drug within 7 half-lives after the last administration of this drug before initiating trial medication, except for subjects entering Part D, who have previously received foscarnet treatment in Part C of this trial. Participation in a clinical trial without receiving other investigational drugs (eg, follow-up phase of a trial, observational study) is permitted. Part E exclusion criteria (Part E is not being conducted in Germany) All exclusion criteria as for Part C, except for exclusion criteria 1, which is replaced by 1. known intolerance to pritelivir or any of the excipients and addition of 14. Having used (val)acyclovir within 3 days prior to starting pritelivir. Part F exclusion criteria All exclusion criteria for Part D plus 14. Part D open for enrollment
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35205
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Garner Melissa
Phone
205-597-6242
Email
mdgarner@uabmc.edu
Facility Name
University Arizona - Department of Medicine Arizona Health Sciences Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martha L. Barron
Phone
520-626-8569
Email
mbarron@arizona.edu
Facility Name
City of Hope
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lindsay Poehlmann
Phone
619-693-8026
Email
Lpoehlman@coh.org
Facility Name
Cedars-Sinai Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maurice Herring
Phone
310-248-7134
Email
Maurice.Herring@cshs.org
First Name & Middle Initial & Last Name & Degree
Allison Peterson
Email
Allison.peterson@csmns.org
Facility Name
University of California, Division of Infectious Diseases
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christine Wangeci Gichigi
Phone
916 734 6942
Email
cwgichigi@ucdavis.edu
First Name & Middle Initial & Last Name & Degree
Jaimie Kimberly Figueroa
Phone
916 734 6942
Email
jkfigueroa@ucdavis.edu
Facility Name
IMMUNOe International Research Centers
City
Centennial
State/Province
Colorado
ZIP/Postal Code
80112
Country
United States
Individual Site Status
Withdrawn
Facility Name
Yale University School of Medicine - Infectious Diseases
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rodolfo N. Molina, M.D.
Phone
203-785-7031
Email
Rodolfo.molina@yale.edu
Facility Name
Midland Florida Clinical Research Center, LLC
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jack Dienes
Phone
386-279-6181
Email
jackdienes.mfcrc@gmail.com
Facility Name
Midway Immunology and Research Center (MIRC)
City
Fort Pierce
State/Province
Florida
ZIP/Postal Code
34982
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carly Sharp
Phone
772-595-9830
Email
info@midwayresearch.com
Facility Name
University of Florida (UF) - Division of Infectious Disease
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steven Fowler
Phone
352-294-5277
Email
stevenfowler@ufl.edu
Facility Name
Palmetto Professional Research
City
Miami
State/Province
Florida
ZIP/Postal Code
33175
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yadira Alfonso
Phone
208-346-8900
Email
yalfonso@palmettoproresearch.com
Facility Name
Links Clinical Trials
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yelamis Cartaya
Phone
305-363-2767
Email
ycartaya@lctrials.com
Facility Name
Emory Hospital Midtown Infectious Disease Clinic
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30308
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joan Lopez
Phone
404-686-5198
Email
jllopez@emory.edu
Facility Name
Department of Medicine J. H. Stroger Hospital of Cook County
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mieoak Bahk
Phone
312-572-4543
Email
mbahk@cookcountyhhs.org
Facility Name
LSU Health Baton Rouge Pulmonary Clinic
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70809
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Daigle
Phone
225-757-4150
Email
jdai11@lsuhsc.edu
Facility Name
Johns Hopkins University School of Medicine
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21205
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Obi Ezennia
Phone
410-614-6702
Email
oezenni1@jhmi.edu
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kerry Crisalli
Phone
617-643-4087
Email
kcrisalli@mgh.harvard.edu
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Natalie Izaguirre
Phone
617-525-9339
Email
NatalieE_Izaguirre@dfci.harvard.edu
Facility Name
Wayne State University
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Individual Site Status
Terminated
Facility Name
University of Nebraska Medical Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68198
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
M. Grace Rodriguez
Phone
402-559-6244
Email
mrodrigu@unmc.edu
Facility Name
David H. Koch Center at Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gyuri Han
Phone
646-608-2776
Email
HanG1@mskcc.org
Facility Name
Atrium Health Wake Forest Baptist
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rica Abbott
Phone
336-713-1395
Email
rabbott@wakehealth.edu
Facility Name
Cincinnati Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kerrigan Perkins
Phone
513-678-8993
Email
kerrigan.perkins@cchmc.org
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angela Pisarra
Phone
412-648-6553
Email
pisarraa@upmc.edu
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-4009
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gloria Araujo
Phone
713-745-6110
Email
gbaraujo@mdanderson.org
Facility Name
Fred Hutchinson Cancer Research Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rachel Blazevic
Phone
206-667-6624
Email
rblazevi@fredhutch.org
Facility Name
Hospital Rawson
City
Córdoba
ZIP/Postal Code
5000
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Viviana David
Phone
+54 351 551 1771
Email
cic.hospitalrawson@gmail.com
Facility Name
Sanatorio Mayo Privado S.A.
City
Córdoba
ZIP/Postal Code
5000
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maximiliano Ambasch
Phone
+54 9 351 805-8266
Email
infectologia_sanroque@yahoo.com.ar
Facility Name
Instituto FIDES
City
La Plata
ZIP/Postal Code
CP 1900
Country
Argentina
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paula Contarelli
Phone
+54 221 5602642
Email
contarellimp@gmail.com
Facility Name
Melbourne Health - Royal Melbourne Hospital
City
Parkville
ZIP/Postal Code
3050
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joanne Patterson
Phone
+61 3 9342 2181
Email
joan.patterson@mh.org.au
Facility Name
Westmead Hospital, Centre for Infectious Disease and Microbiology
City
Westmead
ZIP/Postal Code
2145
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Neela Joshi Rai
Phone
+61 2 8890 6251
Email
Neela.JoshiRai@health.nsw.gov.au
Facility Name
Centre Hospitalier Universitaire Saint Pierre
City
Brussels
ZIP/Postal Code
B1000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Coca Necsoi
Phone
+32 2 535 4747
Email
coca.necsoi@stpierre-bru.be
Facility Name
AZ Delta
City
Roeselare
ZIP/Postal Code
8800
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lies Breyne
Phone
+32 51 23 75 86
Email
lies.breyne@azdelta.be
Facility Name
Alberta Health Services Cross Cancer Institute at the University of Alberta
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kim Robertson
Phone
7804076945
Email
kimberly.robertson2@albertahealthservices.ca
Facility Name
Beijing Ditan Hospital Capital Medical University
City
Beijing
ZIP/Postal Code
100015
Country
China
Individual Site Status
Withdrawn
Facility Name
CHU Limoges - Centre national de reference des Herpes virus
City
Limoges
ZIP/Postal Code
87042
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Françoise Garnier-Geffroy
Phone
+33 5 55 05 55 55
Email
Francoise.GARNIER-GEOFFROY@chu-limoges.fr
Facility Name
CHU de Nantes
City
Nantes
ZIP/Postal Code
44093
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
jeremie orain
Phone
+33 2 5348 2425
Email
jeremie.orain@chu-nantes.fr
Facility Name
Hôpital Saint Louis - AP-HP
City
Paris
ZIP/Postal Code
75010
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
miresta previlon
Phone
+33 1 42 49 99 25
Email
miresta.previlon@aphp.fr
Facility Name
AP-HP Hopital Necker-Enfants Malades
City
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Solimda Sotou Bere
Phone
+33 1 44 49 45 33
Email
solimda.sotoubere@aphp.fr
Facility Name
AP-HP Hopital Bichat - Claude Bernard
City
Paris
ZIP/Postal Code
75018
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lynda Chalal
Phone
+ 33 1 40 25 73 11
Email
lynda.chalal@aphp.fr
Facility Name
LLC Diakor
City
Tbilisi
ZIP/Postal Code
0159
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liza Peikrishvili
Phone
+995 595 30 34 44
Email
liziko5f@yahoo.com
Facility Name
JSC Curatio
City
Tbilisi
ZIP/Postal Code
0168
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nelly Bakuradze
Phone
+995 599 90 23 54
Email
nelly_bakuradze@yahoo.com
Facility Name
Multiprofile Clinic Consilium Medulla LTD
City
Tbilisi
ZIP/Postal Code
0186
Country
Georgia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sopio Ghonghadze
Phone
+995 591 70 89 17
Email
sghonghadze@smo-pharmina.net
Facility Name
Universitätsklinikum Köln
City
Köln
ZIP/Postal Code
50937
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yasmin Habibullah
Phone
+4922147896287
Email
yasmin.habibullah@uk-koeln.de
Facility Name
Muenchen Klinik Neuperlach
City
Muenchen
ZIP/Postal Code
81737
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
baerbel hoell-neugebauer
Phone
+49 89 6794 2737
Email
baerbel.hoell-neugebauer@muenchen-klinik.de
Facility Name
General Hospital of Athens - Laiko
City
Athens
ZIP/Postal Code
11527
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Gamaletsou
Phone
+30 6974957338
Email
magama@med.uoa.gr
Facility Name
Regional University General Hospital of Heraklion
City
Heraklion
ZIP/Postal Code
71110
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Mathioudaki
Phone
+30 69 8360 3822
Email
mailto:mathiouanna94@gmail.com
Facility Name
Chaim Sheba Medical Center
City
Tel-Hashomer
ZIP/Postal Code
5265601
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kira Lozinsky
Phone
+972 3 5305795
Email
Kira.Lozinsky@sheba.health.gov.il
Facility Name
Grande Ospedale Metropolitano "Bianchi Melacrino Morelli"
City
Calabria
ZIP/Postal Code
89133
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gaetana Porto
Phone
+39 0965393886
Email
tania.porto25@hotmail.it
Facility Name
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
City
Milano
ZIP/Postal Code
20122
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giuseppe Lamorte
Phone
+ 39 02 55034036
Ext
4323
Email
giuseppe.lamorte@policlinico.mi.it
Facility Name
Fondazione IRCCS Policlinico San Matteo
City
Pavia
ZIP/Postal Code
27100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alessandra Ferrari
Phone
+39 0382503689
Email
alessandra.ferrari@smatteo.pv.it
Facility Name
Centro de Investigacion Clinica GRAMEL S.C.
City
Distrito Federal
ZIP/Postal Code
03720
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Montserrat Saro
Phone
+52 55 4427 4848
Email
m.saro@gramel.com.mx
Facility Name
Instituto de Investigaciones Aplicadas a la Neurociencia A.C
City
Durango
ZIP/Postal Code
34000
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Berenice Gonzalez
Phone
+526181963882
Email
pichisnichis@gmail.com
Facility Name
Centro de Investigacion Farmaceutica Especializado de Occidente S.C.
City
Guadalajara
ZIP/Postal Code
44160
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Misael Torres
Phone
+52 33 3609 6229
Email
MisaelTorres447@gmail.com
Facility Name
Unidad de Investigacion CIMA SC
City
Monterrey
ZIP/Postal Code
64718
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Flor Gomez
Phone
+52 614 1333520
Email
mailto:florgomex789@gmail.com
Facility Name
Clinical Research Institute Saltillo S.A de C.V
City
Saltillo
ZIP/Postal Code
25020
Country
Mexico
Individual Site Status
Terminated
Facility Name
Arke SMO S.A. de C.V.
City
Veracruz
ZIP/Postal Code
91910
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Reyna Rojas Maulion
Phone
+52 229 931 4102
Email
r.rojas@arke.com.mx
Facility Name
Universitaetsspital Basel Ambulantes Studienzentrum
City
Basel
ZIP/Postal Code
4031
Country
Switzerland
Individual Site Status
Withdrawn
Facility Name
Hopitaux universitaires de Geneve
City
Genève
ZIP/Postal Code
1205
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cristina Boehm-Bosmani
Phone
+41 79 234 15 27
Email
Cristina.Boehm-Bosmani@hcuge.ch
Facility Name
Universitaetsspital Zuerich
City
Zuerich
ZIP/Postal Code
8091
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rheliana Katzensteiner
Phone
+41 442553730
Email
Rheliana.Katzensteiner@usz.ch
Facility Name
Chelsea and Westminster Hospital
City
London
ZIP/Postal Code
SW109NH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
rosalie housman
Phone
+44 203 315 5601
Email
rosalie.housman@nhs.net
Facility Name
Research Department of Haematology, UCL Cancer Institute
City
London
ZIP/Postal Code
WC1E 6BT
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dorothy Marino
Phone
+44 7971775175
Email
dorothy.marino@nhs.net
Facility Name
Freeman Hospital
City
Newcastle Upon Tyne
ZIP/Postal Code
NE7 7DN
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bijal Patel
Phone
+44 01912825045
Email
Bijal.Patel4@nhs.net

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

We'll reach out to this number within 24 hrs